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(FB). The delineation of OARs- bladder wall (BW), rectal wall (RW), 
sigmoid colon & bowel (peritoneal cavity) was done in both scans by a 
radiation oncologist. Both conventional & CT based planning were 
performed on PLATO brachytherapy planning system v14.3.7 
(Nucletron, The Netherlands). Dose volume histograms of OARs wall 
were calculated. The volume doses were defined either as minimum 
dose value in a cm3 volume receiving the highest dose (D0.1cc, D0.2cc, 
D0.5cc, D1cc, D2cc, D5cc, D10cc) or as percentage of volume of OAR 
receiving a dose (D25%, D50%, D100%). The significance of differences was 
compared using two sided paired t test. 
Results: The mean BW volume in EB & FB was 26.2cc (range 17.4-
40.4) & 44.8cc (range 38.5-49.2) respectively. When bladder was 
distended the mean difference in D0.1cc-10cc values for BW & RW 
increased marginally but were not statistically significant. However 
D0.1cc-10cc values for bowel dose (cGy) decreased significantly (0.1 cc. 
698.9 to 492.9 p=0.037, 0.2cc 666.4 to 465.7 p= 0.007, 0.5cc 617.7 to 
427.1 p=0.006, 1 cc 574.4 to 389.8 p=0.005, 2cc 521.4 to 347.9 
p=0.003, 5cc 446.4 to 286.7 p=0.002). In contrast the mean D25%, D50%, 
D100% values for both BW (411.3 vs 244.7, 254.6 vs 123.9, 78.6 vs 
26.2cGy) & bowel decreased (135.3 vs 81.2, 82.5 vs 51.6, 11.1 vs 
4.8cGy) when compared with EB &FB respectively which was 
significant at p=0.000 for all parameters for both OARs but no 
significant difference was seen for RW & sigmoid colon doses. 
Conclusions: Distension of bladder resulted in a significant reduction 
in bowel during image based ICBT without any significant increase in 
the dose to bladder wall, rectal wall and sigmoid colon and can be 
explored in clinical settings. 
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Purpose/Objective: The time course of human papillomavirus (HPV) 
DNA clearance was studied in patients with carcinoma of the cervix 
during follow-up after primary radical radiotherapy (RT). This study 
investigated the relationship between timing of HPV clearance and RT 
effectiveness. 
Materials and Methods: Seventy-two consecutive patients who were 
treated with primary radical RT for cervical cancer were enrolled in 
the study. Samples for HPV DNA examination were taken before: a) 
treatment, b) every brachytherapy, and c) and every follow-up 
examination. The times when HPV DNA was undetected were analyzed 
for association with recurrence free survival. 
Results: HPV DNA was not detected in 13 patients (18%) before RT. Of 
the 59 patients with HPV DNA detected before treatment, HPV DNA 
was not detected in 28% during treatment and in 72% after the 
treatment. Within six months after RT, HPV DNA was detected in 0% of 
all patients. Among the various time points analyzed, patients with no 
detectable HPV DNA before treatment were more accurate predictors 
of recurrence than patients with HPV DNA detected before RT. 
Conclusions: In this study we showed the time course of HPV DNA 
clearance during follow-up of patients with carcinoma of the cervix 
treated with primary radical RT. The patients in whom HPV was not 
detected had the worst prognosis. Six months after RT, HPV DNA was 
detected in 0% of the patients that had shown HPV DNA during 
treatment. In previous reports, those patients with HPV persistence 
after treatment would be considered a high risk group needing more 
effective or additional treatment. This study adds additional 
information on the relationship between detectability of HPV and RT 
effectiveness.  
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Purpose/Objective: We aim to retrospectively review the outcome of 
patients treated for EC with PORT at a single center. The secondary 
goals were identification of prognostic factors, comparison of toxicity 
profiles between vaginal cuff brachytherapy (VB) alone or combined 
with pelvic external beam radiation therapy and VB (EBRT+VB), and 
comparison of severe bladder and intestinal late toxicity (≥ G3) 
between 2D-, 3D-, and IMRT-EBRT+VB. We also investigate the 
incidence of second cancers.  
Materials and Methods: A series of 201 patients treated with PORT 
between 1999 and 2009. Patient's characteristics are summarized in 
table 1. Outcome, toxicity, and incidence of second cancers were 
confirmed by reviewing patient's charts. Overall survival (OS), 
locoregional control (LRC), disease-free survival (DFS), and cancer-
specific survival (CSS) curves were computed, and subgroups were 
compared via lograng test. Cox proportional hazards modeling was 
performed to evaluate the effect of multiple variables. 
 
Patient's characteristics Percentages (%) 
Median age 68 year-old   
Grade 1 32 
Grade 2 43.5 
Grade 3 24.5 
Lymphovascular invasion 32.5 
Stage (FIGO 1988)  
I A-B 28.85 
IC 30.85 
II 25.3 
III-IVA 15 
 
Results: At a median follow-up time of 5 years (range, 1-12), OS was 
78% (95% CI: 72-84%), DFS 72% (95% CI: 65-79%), CSS 84% (95% CI: 79-
89%), and LRC 84% (95% CI: 79-89%), In univariate analyses, significant 
prognostic factors for OS and DFS were age, grade, lymphovascular 
invasion (LVI), stage, cervical invasion, histology, and surgical 
lymphadenectomy. For CSS: histology type, cervical invasion, grade, 
stage, and presence of lymphovascular invasion. The use of 
brachytherapy was associated to better OS, DFS, and CSS in univariate 
analyses but its effect disappeared in multivariate analysis. In the 
multivariate analysis, independent factors influencing the outcome 
were age (OS, DFS), stage (OS, DFS, CSS), LVI (OS, DFS), grade (DFS, 
CSS), and lymphadenectomy (OS). By the end of follow-up, 13% of the 
patients developed severe GI or GU late toxicity, and the cumulative 
incidence of second cancers in the irradiated area was 16%. Five-year 
probability of severe (grade ≥ 3) toxicity was 0% for VB alone vs. 16% 
(95% CI: 9-23%) for EBRT+VB (p = 0.0008). By radiotherapy technique 
toxicity was: 0% for VB alone and 0% for IMRT+VB, 9% (95% CI: 1-17%) 
for 3D-EBRT+VB, and 22% (95% CI: 12-32%) for 2D-EBRT+VB, (p = 
0.0009).  
Conclusions: Local/locoregional recurrence rates remain low after 
surgery and PORT. The use of VB or EBRT+VB should be tailored to the 
surgical and pathologic features. Dependency between toxicity and 
radiotherapy technique is observed. VB alone or IMRT+VB have not 
provoked severe late toxicity. 2D-EBRT more than 3D-EBRT+VB was 
associated with increased severe toxicity. For patients with 
intermediate risk histopathologic features, VB alone seems to be 
sufficient. Comprehensive surgical staging with complete lympha-
denectomy impacts the outcome in this retrospective series. 
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Purpose/Objective: Carnitine palmitoyltransferase 1C (Cpt1c) is a 
brain-specific metabolic enzyme that is involved in energy 
homeostasis and appetite regulation (Wolfgang et al. 2006). We 
further identified Cpt1c as a gene regulated by the p53 transcription 
factor and by the AMP-dependent kinase (AMPK) (Sanchez-Macedo et 
al., accepted in CDD), which helps tumor cells to survive under 
metabolic stress, i.e. glucose deprivation and hypoxia (Zaugg et al. 
2011). To better understand the role of Cpt1c in tumorigenesis we 
need first to elucidate its physiological function, which is still unclear. 
We investigated the impact of loss of Cpt1c function in a mouse tumor 
model and analyzed the metabolic phenotype of a Cpt1c gene trap 
mouse. 
Materials and Methods: We used Nf1+/-:p53+/- mice as a tumor model. 
These Nf1;p53 heterozygous mice develop sarcomas with high 
frequency. These mice were crossbred with mice depleted of Cpt1c 
(Cpt1cgt/gt). The median survival rate of Nf1+/-:p53+/-:Cpt1cgt/gt mice 
was compared with Nf1+/-:p53+/- mice, Cpt1cgt/gt mice and a wild type 
control (C57BL/6 strain). Survival of the mice was plotted using a 
 
